Keyphrases
Chemotherapy
100%
Sarcopenia
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
United States Veterans
100%
Treatment Tolerance
100%
Confidence Interval
37%
Adjusted Odds Ratio
37%
Hospitalization
25%
Treatment-related Mortality
25%
Febrile Neutropenia
25%
Diffuse Large B Cell
25%
Prednisone
12%
Treatment Planning
12%
Overall Survival
12%
Rituximab
12%
Significant Trend
12%
Supportive Care
12%
Doxorubicin
12%
Cyclophosphamide
12%
Retrospective Cohort
12%
Intolerance
12%
Number of Cycles
12%
Body Composition Parameters
12%
Computed Tomography Analysis
12%
Treatment Cycle
12%
CARE Measure
12%
Number of Treatment
12%
Variable Baseline
12%
Medicine and Dentistry
Sarcopenia
100%
Diffuse Large B-Cell Lymphoma
100%
CHOP
100%
Odds Ratio
37%
B Cell
25%
Febrile Neutropenia
25%
Treatment Planning
12%
Overall Survival
12%
Computer Assisted Tomography
12%
Supportive Care
12%
Rituximab
12%
Doxorubicin
12%
Cyclophosphamide
12%
Prednisone
12%
Vincristine
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Diffuse Large B Cell Lymphoma
100%
Sarcopenia
100%
Febrile Neutropenia
25%
Prednisone
12%
Overall Survival
12%
Rituximab
12%
Doxorubicin
12%
Cyclophosphamide
12%
Vincristine
12%